For the past 10 years, Yale Professors David Spiegel and Jason Crawford have been working on tools to enable the development of glucosepane-cleaving drugs. Kizoo Technology Capital investors say now is the time to advance this groundbreaking research toward the clinic and are leading funding of a new company, Revel Pharmaceuticals Inc., founded by Drs. David Spiegel, Jason Crawford, and Aaron Cravens.

Kizoo leads the seed financing round at Revel, with Oculus co-founder Michael Antonov participating. SENS Research Foundation provided funding to the YaleGlycoSENS group for several years.

The Forever Healthy Foundation announces the launch of the "Vascular Rejuvenation using EDTA" Risk-Benefit Analysis.

The team evaluates the use of EDTA chelation therapy and its rejuvenating effects on the cardiovascular system. Potential benefits include stabilization and reduction of atherosclerotic plaque, prevention of epigenetic changes, stabilization of membranes, and a substantial reduction of adverse cardiovascular events such as heart attack and stroke.

Underdog Pharmaceuticals, Kizoo Technology Capital and SENS Research Foundation today announced the launch of Underdog and the completion of its seed round, providing $3.95 million to promote Underdog’s development of disease-modifying treatments for atherosclerosis and other age-related diseases. SRF also announced two senior appointments.

The Forever Healthy Foundation announce the public launch of the Risk-Benefit Analysis of low-level light therapy to rejuvenate the skin.

Low-level light therapy (LLLT) or photobiomodulation is the use of low energy light at a particular wavelength. Targeting the skin, it is supposed to lead to a more youthful appearance through increased collagen and elastin production, and a reduction in age spots and wrinkles.

The Forever Healthy Foundation announces the public launch of the Risk-Benefit Analysis of Fisetin as a Senolytic Therapy, a systematic review of the published evidence.

​It is the second publication of Forever Healthy's "Rejuvenation Now" initiative following the Risk & Benefit Analysis of NAD+ Restoration Therapy.

The Forever Healthy Foundation today announces the public launch of it's "Rejuvenation Now" initiative and the publication of the first results of the project. 

Senolytics, NAD+, Lipid Replacement, Decalcification, mTOR Inhibitors, Geroprotectors, ... - the first generation of human rejuvenation therapies is available today. However, the field is still very young and the information often spotty. New therapies are emerging, and existing ones are updated or replaced. A real challenge for those who want to take advantage of this exciting development as soon as possible.

When building and documenting our individual supplement stacks, we found it quite inconvenient that no single website could be used as a reference for all the compounds that we are using.

Thus we created the Forever Healthy Compound Library as a stable and complete reference for those compounds.

Entries in the library offer a standardized way of linking a compound and quickly accessing the related examine.com, ConsumerLabs, Wikipedia, and pubMed pages. Additionally, we added interesting related media/websites.